These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 8781534)

  • 1. Dopamine, 6-hydroxydopamine, iron, and dioxygen--their mutual interactions and possible implication in the development of Parkinson's disease.
    Linert W; Herlinger E; Jameson RF; Kienzl E; Jellinger K; Youdim MB
    Biochim Biophys Acta; 1996 Aug; 1316(3):160-8. PubMed ID: 8781534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's disease.
    Jellinger K; Linert L; Kienzl E; Herlinger E; Youdim MB
    J Neural Transm Suppl; 1995; 46():297-314. PubMed ID: 8821067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron as catalyst for oxidative stress in the pathogenesis of Parkinson's disease?
    Kienzl E; Jellinger K; Stachelberger H; Linert W
    Life Sci; 1999; 65(18-19):1973-6. PubMed ID: 10576448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Redox reactions of neurotransmitters possibly involved in the progression of Parkinson's Disease.
    Linert W; Jameson GN
    J Inorg Biochem; 2000 Apr; 79(1-4):319-26. PubMed ID: 10830883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elucidation of the interplay between Fe(II), Fe(III), and dopamine with relevance to iron solubilization and reactive oxygen species generation by catecholamines.
    Sun Y; Pham AN; Waite TD
    J Neurochem; 2016 Jun; 137(6):955-68. PubMed ID: 26991725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of transition metals in the pathogenesis of Parkinson's disease.
    Kienzl E; Puchinger L; Jellinger K; Linert W; Stachelberger H; Jameson RF
    J Neurol Sci; 1995 Dec; 134 Suppl():69-78. PubMed ID: 8847547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iron- and manganese-catalyzed autoxidation of dopamine in the presence of L-cysteine: possible insights into iron- and manganese-mediated dopaminergic neurotoxicity.
    Shen XM; Dryhurst G
    Chem Res Toxicol; 1998 Jul; 11(7):824-37. PubMed ID: 9671546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson's disease.
    Soto-Otero R; Méndez-Alvarez E; Hermida-Ameijeiras A; Muñoz-Patiño AM; Labandeira-Garcia JL
    J Neurochem; 2000 Apr; 74(4):1605-12. PubMed ID: 10737618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroprotective effects of erythropoietin on 6-hydroxydopamine-treated ventral mesencephalic dopamine-rich cultures.
    Ganser C; Papazoglou A; Just L; Nikkhah G
    Exp Cell Res; 2010 Mar; 316(5):737-46. PubMed ID: 20060824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of the neurotoxin 6-hydroxydopamine by peroxidase/H2O2 oxidation of dopamine.
    Napolitano A; Crescenzi O; Pezzella A; Prota G
    J Med Chem; 1995 Mar; 38(6):917-22. PubMed ID: 7699708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. l-DOPA administration enhances 6-hydroxydopamine generation.
    Maharaj H; Sukhdev Maharaj D; Scheepers M; Mokokong R; Daya S
    Brain Res; 2005 Nov; 1063(2):180-6. PubMed ID: 16257392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of the Fe(III)-catalyzed dopamine oxidation by ATP and its relevance to oxidative stress in Parkinson's disease.
    Jiang D; Shi S; Zhang L; Liu L; Ding B; Zhao B; Yagnik G; Zhou F
    ACS Chem Neurosci; 2013 Sep; 4(9):1305-13. PubMed ID: 23823941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of oxidative stress, impaired glycolysis and mitochondrial respiratory redox failure in the cytotoxic effects of 6-hydroxydopamine in vitro.
    Mazzio EA; Reams RR; Soliman KF
    Brain Res; 2004 Apr; 1004(1-2):29-44. PubMed ID: 15033417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxidation and cytotoxicity of 6-OHDA are mediated by reactive intermediates of COX-2 overexpressed in PC12 cells.
    Tyurina YY; Kapralov AA; Jiang J; Borisenko GG; Potapovich AI; Sorokin A; Kochanek PM; Graham SH; Schor NF; Kagan VE
    Brain Res; 2006 Jun; 1093(1):71-82. PubMed ID: 16712820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron-mediated generation of the neurotoxin 6-hydroxydopamine quinone by reaction of fatty acid hydroperoxides with dopamine: a possible contributory mechanism for neuronal degeneration in Parkinson's disease.
    Pezzella A; d'Ischia M; Napolitano A; Misuraca G; Prota G
    J Med Chem; 1997 Jul; 40(14):2211-6. PubMed ID: 9216840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of metal-mediated DNA damage and apoptosis induced by 6-hydroxydopamine in neuroblastoma SH-SY5Y cells.
    Kobayashi H; Oikawa S; Umemura S; Hirosawa I; Kawanishi S
    Free Radic Res; 2008 Jul; 42(7):651-60. PubMed ID: 18654880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine transporter-mediated cytotoxicity of 6-hydroxydopamine in vitro depends on expression of mutant alpha-synucleins related to Parkinson's disease.
    Lehmensiek V; Tan EM; Liebau S; Lenk T; Zettlmeisl H; Schwarz J; Storch A
    Neurochem Int; 2006 Apr; 48(5):329-40. PubMed ID: 16406146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rg1 protects iron-induced neurotoxicity through antioxidant and iron regulatory proteins in 6-OHDA-treated MES23.5 cells.
    Xu H; Jiang H; Wang J; Xie J
    J Cell Biochem; 2010 Dec; 111(6):1537-45. PubMed ID: 20872781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reaction of oxygen with 6-hydroxydopamine catalyzed by Cu, Fe, Mn, and V complexes: identification of a thermodynamic window for effective metal catalysis.
    Bandy B; Walter PB; Moon J; Davison AJ
    Arch Biochem Biophys; 2001 May; 389(1):22-30. PubMed ID: 11370668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism Underlying the Effectiveness of Deferiprone in Alleviating Parkinson's Disease Symptoms.
    Sun Y; Pham AN; Waite TD
    ACS Chem Neurosci; 2018 May; 9(5):1118-1127. PubMed ID: 29381045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.